Literature DB >> 11732875

Ogilvie's syndrome in acute myeloid leukemia: pharmacological approach with neostigmine.

M Breccia1, C Girmenia, S Mecarocci, C Cartoni, I Carmosino, A Tafuri, G Alimena.   

Abstract

Acute colonic pseudo-obstruction, the so-called Ogilvie's syndrome, is a rare and life-threatening digestive complication usually observed in critically ill patients. It is characterized by signs of large-bowel obstruction, without a mechanical cause, and has been reported in various settings, including acute leukemias as a complication of neutropenic enterocolitis after intensive chemotherapy. We describe the case of a young woman who, during the neutropenic phase following autologous bone marrow transplantation for relapsed acute myeloid leukemia, developed neutropenic enterocolitis complicated by an acute pseudo-obstruction of descendent colon and sigma. This process was associated with sepsis and resolved with conservative therapy of the underlying condition, using granulocyte colony-stimulating factor and intravenous neostigmine. We discuss the management of this rare syndrome.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11732875     DOI: 10.1007/s002770100337

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  3 in total

1.  Neostigmine for the treatment of acute colonic pseudo-obstruction (ACPO) in pediatric hematologic malignancies.

Authors:  Jae-Wook Lee; Kyong-Won Bang; Pil-Sang Jang; Nak-Gyun Chung; Bin Cho; Dae-Chul Jeong; Hack-Ki Kim; Soo-Ah Im; Gye-Yeon Lim
Journal:  Korean J Hematol       Date:  2010-03-31

2.  Acute abdomen after allogenic hematopoietic stem cell transplantation.

Authors:  Alessandro Crocoli; Daria Pagliara; Franco Locatelli; Alessandro Inserra
Journal:  Pediatr Rep       Date:  2011-12-01

3.  Invasive fungal infections in neutropenic enterocolitis: a systematic analysis of pathogens, incidence, treatment and mortality in adult patients.

Authors:  Marcus Gorschlüter; Ulrich Mey; John Strehl; Volker Schmitz; Christian Rabe; Katharina Pauls; Carsten Ziske; Ingo G H Schmidt-Wolf; Axel Glasmacher
Journal:  BMC Infect Dis       Date:  2006-02-26       Impact factor: 3.090

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.